Baseline results from the Norwegian radiology-led lung cancer screening pilot
DOI:
https://doi.org/10.2340/1651-226X.2026.44910Keywords:
Lung cancer, Low-Dose Computed Tomography, screening program, early-stageAbstract
Background and purpose: Implementation of low-dose computed tomography (LDCT) screening for lung cancer is recommended. The Norwegian Lung Cancer Screening pilot (TIDL) has been conducted to explore recruitment strategy, detection rate and the value of a radiology-led screening program. This publication presents baseline results from the screened participants.
Patient/material and methods: All 125,095 individuals aged 60–79 years in Akershus county, Norway were invited to participate. Ever-smokers completed a risk questionnaire based on the PLCOm2012NoRace model: those with ≥35 pack-years or a ≥2.6% 6-year lung cancer risk were eligible for inclusion. Of 2,499 eligible participants, 1,006 underwent baseline LDCT between August 2022 and May 2023, and up to two more rounds later. Nodules were categorized by Lung-RADS v2022. Follow-up and staging were managed by thoracic radiologists; High-suspicion cases were referred to pulmonologists.
Results: At baseline, lung cancer was diagnosed in 23 participants (2.3%), whereof 19 (83%) in stage I and 2 (9%) in stage II. Most underwent curative treatment, primarily robot-assisted surgery. Only 2.9% of the screened individuals were referred for further diagnostic evaluation. The false positive rate was 0.6% after pulmonologist referral and 1.7% after radiological staging. A total of 13.8% required 3- or 6-month imaging follow-up. Complication rates from diagnostic procedures were low.
Interpretation: LDCT screening using combined risk-based eligibility and a radiology-led model is feasible and effective in the Norwegian context. The high detection rate and low clinical burden support its potential for national implementation. These findings may guide the development of future lung cancer screening programs in the Nordic countries and beyond.
Downloads
References
de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503–13.
https://doi.org/10.1056/NEJMoa1911793 DOI: https://doi.org/10.1056/NEJMoa1911793
National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.
https://doi.org/10.1056/NEJMoa1102873 DOI: https://doi.org/10.1056/NEJMoa1102873
Safety D-GfHaF. Proposal for a Council Recommendation (CR) on Strengthening prevention through early detection: A new approach on cancer screening replacing CR 2003/878/EC 2022 [updated 2022 Sep 20]. [cited 2025 May 26]. Available from: https://health.ec.europa.eu/publications/proposal-council-recommendation-cr-strengthening-prevention-through-early-detection-new-approach_en
van der Aalst CM, Ten Haaf K, de Koning HJ. Implementation of lung cancer screening: what are the main issues? Transl Lung Cancer Res. 2021;10(2):1050–63.
https://doi.org/10.21037/tlcr-20-985 DOI: https://doi.org/10.21037/tlcr-20-985
Tammemagi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368(8):728–36.
https://doi.org/10.1056/NEJMoa1211776 DOI: https://doi.org/10.1056/NEJMoa1211776
Nguyen OTD, Fotopoulos I, Markaki M, Tsamardinos I, Lagani V, Røe OD. Improving lung cancer screening selection: The HUNT lung cancer risk model for ever-smokers versus the NELSON and 2021 United States preventive services task force criteria in the cohort of Norway: a population-based prospective study. JTO Clin Res Rep. 2024;5(4):100660.
https://doi.org/10.1016/j.jtocrr.2024.100660 DOI: https://doi.org/10.1016/j.jtocrr.2024.100660
Hubert J, Moldovanu D, van den Bosch I, de Nijs K, Haaf KT, Oudkerk M, et al. Impact of recruitment method on informed decision-making in lung cancer screening in the 4-IN-THE-LUNG-RUN trial. Lung Cancer. 2025;207:108686.
https://doi.org/10.1016/j.lungcan.2025.108686 DOI: https://doi.org/10.1016/j.lungcan.2025.108686
van der Aalst C, Vonder M, Hubert J, Moldovanu D, Schmitz A, Delorme S et al. P1.14-04 European lung cancer screening implementation: 4-IN-THE-LUNG-RUN trial. J Thorac Oncol. 2023;18(11):S217.
https://doi.org/10.1016/j.jtho.2023.09.352. DOI: https://doi.org/10.1016/j.jtho.2023.09.352
Tammemägi MC, Darling GE, Schmidt H, Walker MJ, Langer D, Leung YW, et al. Risk-based lung cancer screening performance in a universal healthcare setting. Nat Med. 2024;30(4):1054–64.
https://doi.org/10.1038/s41591-024-02904-z DOI: https://doi.org/10.1038/s41591-024-02904-z
Pedersen JH, Ashraf H, Dirksen A, Bach K, Hansen H, Toennesen P, et al. The Danish randomized lung cancer CT screening trial – overall design and results of the prevalence round. J Thorac Oncol. 2009;4(5):608–14.
https://doi.org/10.1097/JTO.0b013e3181a0d98f DOI: https://doi.org/10.1097/JTO.0b013e3181a0d98f
Pasquinelli MM, Tammemagi MC, Kovitz KL, Durham ML, Deliu Z, Rygalski K, et al. Risk prediction model versus united states preventive services task force lung cancer screening eligibility criteria: reducing race disparities. J Thorac Oncol. 2020;15(11):1738–47.
https://doi.org/10.1016/j.jtho.2020.08.006 DOI: https://doi.org/10.1016/j.jtho.2020.08.006
Lung Rads. 2022. [cited 2024 May 23]. Available from: https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Reporting-and-Data-Systems/Lung-RADS
Oudkerk M, Devaraj A, Vliegenthart R, Henzler T, Prosch H, Heussel CP, et al. European position statement on lung cancer screening. Lancet Oncol. 2017;18(12):e754–66.
https://doi.org/10.1016/S1470-2045(17)30861-6 DOI: https://doi.org/10.1016/S1470-2045(17)30861-6
Ashraf H, Dirksen A, Loft A, Bertelsen AK, Bach KS, Hansen H, et al. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning. Thorax. 2011;66(4):315–9.
https://doi.org/10.1136/thx.2010.136747 DOI: https://doi.org/10.1136/thx.2010.136747
Xu DM, Gietema H, de Koning H, Vernhout R, Nackaerts K, Prokop M, et al. Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer. 2006;54(2):177–84.
https://doi.org/10.1016/j.lungcan.2006.08.006 DOI: https://doi.org/10.1016/j.lungcan.2006.08.006
Gohagan J, Marcus P, Fagerstrom R, Pinsky P, Kramer B, Prorok P, Writing Committee LSSRG. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute. Chest. 2004;126(1):114–21.
https://doi.org/10.1378/chest.126.1.114 DOI: https://doi.org/10.1378/chest.126.1.114
van Klaveren RJ, Oudkerk M, Prokop M, Scholten ET, Nackaerts K, Vernhout R, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med. 2009;361(23):2221–9.
https://doi.org/10.1056/NEJMoa0906085 DOI: https://doi.org/10.1056/NEJMoa0906085
National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Clapp JD, Clingan KL, et al. Baseline characteristics of participants in the randomized national lung screening trial. J Natl Cancer Inst. 2010;102(23):1771–9.
https://doi.org/10.1093/jnci/djq434 DOI: https://doi.org/10.1093/jnci/djq434
Hammer MM, Byrne SC, Kong CY. Factors influencing the false positive rate in CT lung cancer screening. Acad Radiol. 2022;29(Suppl 2):S18–22.
https://doi.org/10.1016/j.acra.2020.07.040 DOI: https://doi.org/10.1016/j.acra.2020.07.040
Wille MM, Dirksen A, Ashraf H, Saghir Z, Bach KS, Brodersen J, et al. Results of the randomized Danish lung cancer screening trial with focus on high-risk profiling. Am J Respir Crit Care Med. 2016;193(5):542–51.
https://doi.org/10.1164/rccm.201505-1040OC DOI: https://doi.org/10.1164/rccm.201505-1040OC
Ruud EA, Stavem K, Geitung JT, Borthne A, Søyseth V, Ashraf H. Predictors of pneumothorax and chest drainage after percutaneous CT-guided lung biopsy: A prospective study. Eur Radiol. 2021;31(6):4243–52.
https://doi.org/10.1007/s00330-020-07449-6 DOI: https://doi.org/10.1007/s00330-020-07449-6
Helsedirektoratet. Utredning av lungekreftscreening i Norge. Oslo: Helsedirektoratet (siste faglige endring 04. februar 2025, lest 19. desember 2025). 2025. [cited 2025 Dec 20]. Available from: https://www.helsedirektoratet.no/nyheter/utredning-av-lungekreftscreening-i-norge
Wichmann V, Iivanainen S, Mattila L, Kokkonen VP, Jartti A, Kurtti A, et al. Lung cancer screening in Finland: a prospective randomized trial. Acta Oncol. 2025;64:769–74.
https://doi.org/10.2340/1651-226X.2025.43093 DOI: https://doi.org/10.2340/1651-226X.2025.43093
O Reilly D, Roche S, Noonan C, O’Shea J, Toomey S, Hennessy BT, et al. Lung Health Check pilot: Ireland’s flagship lung cancer screening trial. BMJ Open Respir Res. 2025;12(1):e003035.
https://doi.org/10.1136/bmjresp-2024-003035 DOI: https://doi.org/10.1136/bmjresp-2024-003035
Grenier PA, Arutkin M, Brun AL, Métivier AC, Sage E, Haziza F, et al. Prevalent findings on low-dose CT scan lung cancer screening: a French prospective pilot study. Eur J Public Health. 2025;35(2):342–6.
https://doi.org/10.1093/eurpub/ckae183 DOI: https://doi.org/10.1093/eurpub/ckae183
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Albin Mahovkic, Kirill Neumann, Trond-Eirik Strand, Oluf Dimitri Røe, Haseem Ashraf
This work is licensed under a Creative Commons Attribution 4.0 International License.
